Best Agrolife (539660) Q3 24/25 earnings summary

Executive summary

• Q3 FY2025 revenue declined significantly due to adverse weather in South India, reduced crop cycles, and weak demand from key crops, resulting in lower sales and delayed payments.

• The company is shifting towards a B2C model with an expanded branded product portfolio and dealer network, increasing short-term costs and pressuring margins.

• Branded sales rose to 72% of total sales in 9M FY25, but price erosion and reduced demand offset volume growth.

• Strategic partnership formed with Shanghai E-Tong Chemical Co. for joint R&D and manufacturing, and new patents were granted in Africa and India for key products and processes.

• Board approved unaudited standalone and consolidated results for Q3 and nine months ended 31 Dec 2024; results reviewed by statutory auditors.

Financial highlights

• Q3 FY2025 consolidated revenue was ₹315.18 crore (down from ₹315 crore in Q3 FY2024), with a net loss of ₹24.16 crore, mainly due to weak demand and a foreign currency loss of ₹11.36 crore.

• EBITDA (excluding other income) was negative ₹6 crore, with an EBITDA margin of -2%.

• Gross margin improved from 23% in Q3 FY2024 to 32% in Q3 FY2025, driven by higher branded product sales.

• Cash flow from operations was ₹177 crore for nine months and ₹32 crore for the quarter.

• 9M FY25 consolidated net profit was ₹91.78 crore, down from ₹179 crore in 9M FY24.

Outlook and guidance

• FY2025 revenue will not reach the previously guided ₹2,000+ crore due to lower technical sales and underperformance in key southern states; profitability and gross margins are expected to improve but not to previous highs.

• Q4 FY2025 is expected to be better than last year, with lower losses, and FY2026 is projected to see improved performance from cost optimization and new patented products.

• Continued investment in R&D, IP generation, and new product development, with plans to launch new patented herbicide and fungicide products in FY25.

• Management has not identified the need for adjustments in results due to ongoing tax investigation; no changes to business outlook disclosed.